Alirezaei et al. has disclosed in a human study, that Atg5 overexpression in serum and peripheral T cells is associated with the vigorous RRMS symptoms, proposing that Atg5 may be used as a possible therapeutic target for MS treatment [28]. This evidence concerns the gene ATG5 and myeloid sarcoma.